CN110759866A - Metronidazole-glutamine dipeptide compound and preparation and application thereof - Google Patents
Metronidazole-glutamine dipeptide compound and preparation and application thereof Download PDFInfo
- Publication number
- CN110759866A CN110759866A CN201910931094.7A CN201910931094A CN110759866A CN 110759866 A CN110759866 A CN 110759866A CN 201910931094 A CN201910931094 A CN 201910931094A CN 110759866 A CN110759866 A CN 110759866A
- Authority
- CN
- China
- Prior art keywords
- metronidazole
- glutamine dipeptide
- compound
- glutamine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a metronidazole glutamine dipeptide compound, 2- (2-methyl-5-nitro-1H-imidazolyl) ethyl-L-alanyl-L-glutamic acid, the molecular formula is as follows: c14H22N6O6. The invention utilizes the special status of glutamine dipeptide in the body and the important role played by glutamine dipeptide in resisting inflammation to modify glutamine dipeptide to metronidazole, obviously increases the total number of lymphocytes, T lymphocytes and the ratio of CD4/CD8 in circulation of a patient by providing exogenous glutamine, increases the immunologic function of the body, enhances the antibacterial effect of metronidazole, particularly enhances the inhibiting effect of the metronidazole on helicobacter pylori, greatly increases the market prospect of metronidazole modifiers, and has strong practicability and wide applicability.
Description
Technical Field
The invention relates to a metronidazole-glutamine dipeptide compound, in particular to a metronidazole-glutamine dipeptide compound and preparation and application thereof.
Background
Metronidazole (metronidazo1e), also known as metronidazole, is a nitroimidazole antibiotic, has powerful bactericidal action on gram-positive and gram-negative anaerobic bacteria and bacteroides fragilis, and is a clinically common anti-infection basic drug. With the clinical wide application of metronidazole and the continuous and deep research on the pharmacological mechanism of metronidazole, various documents report that the adverse reaction of metronidazole is rare.
Helicobacter pylori (Hp) is a gram-negative, sigmoidal or arcuately curved bacterium, and it has been shown through epidemiological, clinical and pathological studies that Hp can induce chronic gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue (muco-associated lymphoma) lymphoma, intestinal gastric cancer in humans. The world health organization has listed helicobacter pylori as a class I carcinogen, which is a major causative factor of gastric cancer.
Therefore, there is a need for metronidazole modifications that improve its pharmacological action against gram-positive and gram-negative anaerobes, especially against helicobacter pylori, and reduce its adverse effects.
Disclosure of Invention
In order to solve the defects of the prior art, the invention aims to provide a metronidazole-glutamine dipeptide compound capable of enhancing the bacteriostatic effect of metronidazole and a preparation method thereof.
In order to achieve the above object, the present invention adopts the following technical solutions:
a metronidazole-glutamine dipeptide compound has a molecular formula as follows: c14H22N6O6The structural formula is as follows:
the metronidazole-glutamine dipeptide compound is prepared according to the following reaction formula:
the preparation method of the metronidazole-glutamine dipeptide compound comprises the following steps:
s1, dissolving metronidazole (compound 1) and glutamine dipeptide (compound 2) into a proper amount of dichloromethane solution, simultaneously adding a certain amount of DCC and DMAP, stirring for reaction, and then distilling under reduced pressure to obtain a crude product;
s2, purifying the crude product by column chromatography to obtain white powder (compound 3).
Further, in the step S1, the molar ratio of metronidazole (compound 1) to glutamine dipeptide (compound 2) is 1: 1.1.
Further, the DCC was 1.5equiv, and DMAP was 0.3 equiv.
Further, in the above step S1, the reaction was followed by TLC.
The metronidazole-glutamine dipeptide compound is applied to inhibiting helicobacter pylori.
The invention has the advantages that:
glutamine dipeptide is the most abundant free amino acid in the body, accounting for about 60% of the total free amino acid in the body. Glutamine dipeptide can promote mitosis, differentiation and proliferation of lymphocyte and macrophage, increase production of cell factors TNF, IL-1, etc. and synthesis of phospholipid mRNA.
The metronidazole-glutamine dipeptide compound of the invention modifies glutamine dipeptide on metronidazole by utilizing the special position of the glutamine dipeptide in an organism and the important role of the glutamine dipeptide in resisting inflammation, obviously increases the total number of lymphocytes of a patient, the ratio of T lymphocytes to CD4/CD8 in circulation by providing exogenous glutamine, increases the immunologic function of the organism, enhances the antibacterial effect of the metronidazole, particularly enhances the inhibition effect of the exogenous glutamine on helicobacter pylori, greatly increases the market prospect of the metronidazole modifier, and has strong practicability and wide applicability.
Detailed Description
The following specific examples are intended to illustrate the invention.
The reagents used in the examples of the present invention are all commercially available.
DCC is dicyclohexylcarbodiimide and DMAP is 4-dimethylaminopyridine.
A metronidazole-glutamine dipeptide compound, namely 2- (2-methyl-5-nitro-1H-imidazolyl) ethyl-L-alanyl-L-glutamic acid, has a molecular formula as follows: c14H22N6O6The structural formula is as follows:
the reaction formula is as follows:
the preparation method comprises the following steps:
s1, dissolving metronidazole (compound 1)200mg and glutamine dipeptide (compound 2)279mg in a proper amount of dichloromethane solution according to the molar ratio of 1:1.1, simultaneously adding 1.5equiv DCC and 0.3equiv DMAP, stirring and reacting at room temperature, tracking and reacting by TLC, and after the reaction is completed, distilling under reduced pressure to obtain a crude product;
s2, purification of the crude product by column chromatography gave a white powder (compound 3) (385mg, 89% yield).1H NMR(500MHz,CDCl3)δ7.89(s,1H),7.61(d,J＝11.5Hz,1H),6.83(s,2H),6.57(dd,J＝7.9,6.4Hz,1H),6.48(dd,J＝7.8,6.3Hz,1H),4.63–4.52(m,2H),4.48–4.32(m,2H),4.17(q,J＝11.5Hz,1H),4.07(tq,J＝6.2,5.4Hz,1H),2.44(s,3H),2.39–2.22(m,2H),2.03–1.85(m,2H),1.42(d,J＝5.3Hz,3H)。
And (3) detecting the effect of the metronidazole glutamine dipeptide compound on inhibiting the helicobacter pylori:
(I) test materials
Culture medium: nutrient agar
Fresh defibered horse blood
Starch
Mixing antibiotics: vancomycin, a xanthamine synergist TMP, amphotericin and polymyxin
Experimental strains: helicobacter pylori
The medicine solvent is as follows: ethanol
(II) culturing helicobacter pylori
The culture conditions are as follows: the temperature is 37 ℃, the pH value is 7.0-7.2, and the oxygen content is 2-8%
Culture medium: adding appropriate amount of horse blood, appropriate amount of mixed antibiotics and 1% starch into nutrient agar culture medium
Culturing time: 3-5 days
(III) the result of the detection
The experimental components were divided into four groups: filter paper without any drug, filter paper with metronidazole (10mg/mL), filter paper with compound 2 (dipeptide complex of 10mg/mL), filter paper with compound 3 (metronidazole-glutamine dipeptide complex of 10mg/mL)
After the bacteria are cultured, the size of the inhibition zone is measured by a conventional filter paper diffusion method to carry out a drug sensitivity experiment, and the experiment results are shown in the following table 1:
TABLE 1 inhibitory Effect of different Compounds on helicobacter pylori
| Components | Has no drug effect | Compound 2 | Metronidazole | Compound 3 |
| Size/ratio of zone of inhibition | 0 | 0.13 | 1 | 1.8 |
As can be seen from the experimental results in table 1 above, compound 3, i.e., the metronidazole-glutamine dipeptide compound of the present invention, has an inhibitory effect on helicobacter pylori that is significantly greater than metronidazole.
The foregoing illustrates and describes the principles, general features, and advantages of the present invention. It should be understood by those skilled in the art that the above embodiments do not limit the present invention in any way, and all technical solutions obtained by using equivalent alternatives or equivalent variations fall within the scope of the present invention.
Claims (7)
1. A metronidazole-glutamine dipeptide compound is characterized in that the molecular formula is as follows: c14H22N6O6The structural formula is as follows:
2. the preparation of a metronidazole-glutamine dipeptide compound according to claim 1 characterised in that the reaction is as follows:
3. the preparation of a metronidazole-glutamine dipeptide compound according to claim 1, comprising the steps of:
s1, dissolving metronidazole (compound 1) and glutamine dipeptide (compound 2) into a proper amount of dichloromethane solution, simultaneously adding a certain amount of DCC and DMAP, stirring for reaction, and then distilling under reduced pressure to obtain a crude product;
s2, purifying the crude product by column chromatography to obtain white powder (compound 3).
4. The preparation of metronidazole-glutamine dipeptide compounds according to claim 3, wherein the molar ratio of metronidazole (compound 1) to glutamine dipeptide (compound 2) in step S1 is 1: 1.1.
5. The preparation of a family of metronidazole glutamine dipeptide compounds according to claim 3 where the DCC is 1.5equiv and the DMAP is 0.3 equiv.
6. The method for preparing metronidazole glutamine dipeptide compound according to claim 3, wherein in step S1 the reaction is followed by TLC.
7. The use of a metronidazole proglumide dipeptide compound according to claim 1 in the inhibition of helicobacter pylori.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910931094.7A CN110759866B (en) | 2019-09-29 | 2019-09-29 | Metronidazole-glutamine dipeptide compound and preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910931094.7A CN110759866B (en) | 2019-09-29 | 2019-09-29 | Metronidazole-glutamine dipeptide compound and preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110759866A true CN110759866A (en) | 2020-02-07 |
| CN110759866B CN110759866B (en) | 2022-12-27 |
Family
ID=69330846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910931094.7A Active CN110759866B (en) | 2019-09-29 | 2019-09-29 | Metronidazole-glutamine dipeptide compound and preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110759866B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113072503A (en) * | 2021-03-23 | 2021-07-06 | 右江民族医学院 | Linolenic acid-metronidazole compound and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106467494A (en) * | 2015-08-21 | 2017-03-01 | 陕西合成药业股份有限公司 | Amino-acid ester soluble derivative of laevo-ornidazole and application thereof |
-
2019
- 2019-09-29 CN CN201910931094.7A patent/CN110759866B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106467494A (en) * | 2015-08-21 | 2017-03-01 | 陕西合成药业股份有限公司 | Amino-acid ester soluble derivative of laevo-ornidazole and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| CINZIA BERSANI，等: "PEG-metronidazole conjugates: synthesis, in vitro and in vivo properties", 《IL FARMACO》, 22 July 2005 (2005-07-22), pages 783 - 788 * |
| MOHAMED A. IBRAHIM，等: "Synthesis and antibacterial evaluation of amino acid–antibiotic conjugates", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, 30 January 2014 (2014-01-30), pages 1856 - 1861 * |
| PERMENTIER, DIRK，等: "Synthesis of dipeptide esters of metronidazole and evaluation of their hydrolytic stability", 《BULLETIN DES SOCIETES CHIMIQUES BELGES》, 31 December 1992 (1992-12-31), pages 701 - 707 * |
| RINKU BAISHYA，等: "Synthesis and Evaluation of Technetium-99m-Labeled Bioreductive Pharmacophores Conjugated with Amino Acids and Peptides for Tumor Imaging", 《CHEM BIOL DRUG DES》, 31 December 2015 (2015-12-31), pages 504 - 517 * |
| ROMAN N. NAUMOV，等: "Synthesis and QSAR study of novel anti-inflammatory active mesalazine–metronidazole conjugates", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, 13 April 2015 (2015-04-13), pages 2314 - 2320, XP029228576, DOI: 10.1016/j.bmcl.2015.04.023 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113072503A (en) * | 2021-03-23 | 2021-07-06 | 右江民族医学院 | Linolenic acid-metronidazole compound and preparation method and application thereof |
| CN113072503B (en) * | 2021-03-23 | 2022-02-01 | 右江民族医学院 | Linolenic acid-metronidazole compound and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110759866B (en) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113072611B (en) | Preparation method of glycyrrhetinic acid modified polypyridine ruthenium complex antibacterial agent | |
| CN107475146B (en) | Application of streptomyces and metabolite piericidin compound thereof in resisting kidney cancer | |
| CN110759866B (en) | Metronidazole-glutamine dipeptide compound and preparation and application thereof | |
| CN110551072A (en) | quinoxaline-N 1, N 4 -dioxide derivative with DNA topoisomerase activity inhibition function, preparation method and application | |
| CN112111410B (en) | Preparation method of dibenzooxepinone compound | |
| CN111217706B (en) | Marine polyketide hypoxone A, preparation method thereof and application thereof in preparing anti-inflammatory drugs | |
| CN114651898B (en) | Triazole feed additive for improving immunity as well as preparation method and application thereof | |
| CN110642922B (en) | Metronidazole-serine dipeptide compounds and preparation and application thereof | |
| CN103864638B (en) | A kind of benzoic acid derivative and its preparation method and application | |
| CN110713515B (en) | Metronidazole-sarcosyl-histidine dipeptide compound and preparation and application thereof | |
| CN110669100B (en) | Metronidazole serine-asparagine dipeptide compound and preparation and application thereof | |
| CN113402565B (en) | Tetravalent platinum complex containing posaconazole, preparation method and application thereof | |
| CN104031051A (en) | Diketopiperazines and preparation method and application thereof | |
| CN114751863A (en) | Terestacin derivative, preparation method thereof and application of Terestacin derivative in preparation of low-oxygen factor inhibitor | |
| CN108794502B (en) | Trichothecene compound and preparation method and application thereof | |
| CN107973803B (en) | Seven-membered lactonofuran derivative and preparation method and application thereof | |
| CN110002996B (en) | Diphenyl ether compound and preparation method and application thereof | |
| CN110627865B (en) | Metronidazole-phenylalanyl-lysine dipeptide compound and preparation and application thereof | |
| CN112480031A (en) | Emodin amide derivatives containing 1,3, 4-thiadiazole, and synthesis method and application thereof | |
| CN113444131A (en) | N-acetylglucosamine compounds, and preparation method and application thereof | |
| CN102051394A (en) | Preparation method and application of sulfo-diketopiperazine compounds | |
| UMEZAWA et al. | Isolation from Streptomyces of a novel naphthoquinone compound, naphthablin, that inhibits Abl oncogene functions | |
| CN1268630C (en) | Synthesis for compound of diamine bridge linking ortho phenanthroline hydrous lanthanum (III) and anti-cancer activity thereof | |
| CN109206337B (en) | Diphenyl acid compounds derived from sandalwood endophytic fungi, preparation method thereof and application thereof in preparation of antibacterial drugs | |
| CN108660169A (en) | A method of fermentation prepares spine spore bacteriums antibiotic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |